Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,529.50
Bid: 1,531.50
Ask: 1,532.00
Change: 3.50 (0.23%)
Spread: 0.50 (0.033%)
Open: 1,537.00
High: 1,541.50
Low: 1,523.00
Prev. Close: 1,526.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Taihua Total Sales Up For 2014 As Price Increase Offsets Lower Harvest

Thu, 19th Feb 2015 11:41

LONDON (Alliance News) - Taihua PLC Thursday said its total sales rose to CNY53.1 million from CNY2.3 million in 2013, as the wholesale price of forsythia compensated for a reduced harvest.

Taihua is a China based pharmaceutical company specialising in traditional Chinese medicine and some active pharmaceutical ingredients.

The company saw a total harvest of 1,145 tonnes of forsythia, down from 1,528.6 tonnes in the previous year, due to adverse weather conditions. The company said other suppliers saw a similar shortfall which helped increase wholesale prices.

The average selling price rose to CNY37.77 per kilogram from CNY28.31 per kilogram excluding sales tax. The entire harvest was sold.

Taihua said it was still seeking to extend the distribution of Chinese traditional medicine Bian Tong Pian. At the time of its interim results, the company said it had been unable to extend distribution of Bian Tong Pian due to the impact of the GlaxoSmithKline PLC bribery allegations in China.

"The problems surrounding GlaxoSmithKline in China and associated investigations into the distribution of pharmaceuticals by the Chinese government has left distributors reluctant to take on new products. For the time being, given the government focus on this industry, they prefer to adopt a very conservative approach and only distribute their existing products," it said at the time.

The company said Thursday that the profitability of its active pharmaceutical ingredient paclitaxel has been reduced, and in 2014 it was loss-making at a gross margin levels as by-products had not been successfully sold. As a result, it will cease production of paclitaxel for an initial six months with immediate effect.

After this time, it will assess what the withdrawal from production has done to the Chinese wholesale price, and then make a further decision on the future of the product.

Sales of ingredient homoharringtonine continued at the low level it has seen in recent years, it said. However, Taihua will continue to produce the ingredient as historically the product has been important due to its volume and margin, and it expects a return to earlier market conditions.

Taihua said it was working with agronomists to look for ways to enhance the harvest from its plantations.

Shares in Taihua are trading up 6.7% at 4.00 pence Thursday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
27 Jun 2023 08:21

GSK granted US FDA fast track for gonorrhoea vaccine

(Alliance News) - GSK PLC on Tuesday reported that the US Food & Drug Administration has granted its gonorrhoea investigational vaccine a "fast track" designation.

Read more
27 Jun 2023 08:07

GSK gonorrhoea vaccine gets FDA fast track designation

(Sharecast News) - GSK said on Tuesday that its investigational vaccine for sexually transmitted infection gonorrhoea has been granted a fast track designation by the US Food and Drug Administration.

Read more
27 Jun 2023 07:56

LONDON BRIEFING: Stocks called up; record profit for Telecom Plus

(Alliance News) - Stock prices in London were set to open higher on Tuesday, following a positive session for equities in Hong Kong and Shanghai.

Read more
26 Jun 2023 08:38

TOP NEWS: GSK hails approvals for drug therapies in Japan and Europe

(Alliance News) - GSK PLC on Monday celebrated several regulatory approvals for new drug therapies, including treatments for shingles.

Read more
26 Jun 2023 07:56

LONDON BRIEFING: Stocks firm; Aston Martin signs Lucid, Mercedes deals

(Alliance News) - Stocks in London were set to start the new week marginally lower, with financial markets unfazed by a failed revolt by a mercenary army in Russia over the weekend.

Read more
26 Jun 2023 07:43

GSK gets an approval in Japan, a recommendation in Europe

(Sharecast News) - GSK announced two significant advancements on Monday, with the approval of an updated indication for Shingrix in Japan, as well as a positive opinion from the European Medicines Agency for daprodustat.

Read more
23 Jun 2023 20:24

GSK soothes investors by settling first Zantac cancer lawsuit due for US trial

GSK shares best performer on London's stock market

*

Read more
23 Jun 2023 17:25

DIRECTOR DEALINGS: GSK CFO buys shares worth GBP321,500

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Friday and not separately reported by Alliance News:

Read more
23 Jun 2023 17:21

European shares post worst week in three months, Siemens Energy slumps

Siemens Energy weighs on German stocks

*

Read more
23 Jun 2023 17:17

London stocks log sharp weekly declines as rate hike pressures mount

UK shoppers boost spending again in May

*

Read more
23 Jun 2023 16:58

LONDON MARKET CLOSE: Stocks end in the red as recession fears mount

(Alliance News) - Stocks in London closed lower on Friday as weak economic data and the prospect of global interests staying higher for longer put investors in a firmly risk-off mood.

Read more
23 Jun 2023 12:41

The best-is-yet-to-come narrative fades

Euro zone business growth stalls in June -flash PMI

*

Read more
23 Jun 2023 12:09

LONDON MARKET MIDDAY: Housebuilders bear brunt of rate hike worries

(Alliance News) - Stock prices in London were lower heading into Friday afternoon, as a poor week for equities continued, with investors fretting over the prospect of central banks keeping interest rates higher for longer.

Read more
23 Jun 2023 10:20

‘Dictator? That’S Absurd’: a guide for investors navigating U.S.-China tensions

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

‘DICTATOR? THAT’S ABSURD’: A GUIDE FOR INVESTORS NAVIGATING U.S.-CHINA TENSIONS (0915 GMT)

Read more
23 Jun 2023 09:40

PMIs in focus as healthcare staves off deeper losses

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

PMIS IN FOCUS, HEALTHCARE STAVES OFF DEEPER LOSSES (0840 GMT)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.